Skip to content

Study · Randomized controlled trial · n = 36 · 2001

11 results

Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women.

Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R

Fertility and sterility1 Feb 2001Cited by 29 (Europe PMC)

PMID11172833 (opens in a new tab)DOI10.1016/s0015-0282(00)01702-7 (opens in a new tab)PepBankPUB-11172833
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy premenopausal women, plasma cetrorelix AUC increased proportionally with dose.

    In plain wordsIn healthy premenopausal women, plasma cetrorelix exposure increased proportionally with dose.

    Peptide
    Cetrorelix
    Outcome
    IncreasePlasma AUC dose proportionality
    Study

    n = 36

    Comparator
    Other cetrorelix doses
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1-5 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    The area under the concentration-time curve (AUC) and peak cetrorelix concentrations in plasma (Cmax) increased proportionally with dose.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In healthy premenopausal women, peak plasma cetrorelix concentrations increased proportionally with dose.

    In plain wordsIn healthy premenopausal women, peak plasma cetrorelix concentrations increased proportionally with dose.

    Peptide
    Cetrorelix
    Outcome
    IncreasePlasma Cmax dose proportionality
    Study

    n = 36

    Comparator
    Other cetrorelix doses
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1-5 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    The area under the concentration-time curve (AUC) and peak cetrorelix concentrations in plasma (Cmax) increased proportionally with dose.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy premenopausal women, cetrorelix rapidly and reversibly suppressed serum LH.

    In plain wordsIn healthy premenopausal women, cetrorelix rapidly and reversibly suppressed serum LH.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSerum LH suppression
    Study

    n = 36

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1, 3, or 5 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Cetrorelix acetate administration led to a rapid, marked, and reversible suppression of serum LH, E2, and to a lesser extent FSH concentrations.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy premenopausal women, cetrorelix rapidly and reversibly suppressed serum E2.

    In plain wordsIn healthy premenopausal women, cetrorelix rapidly and reversibly suppressed serum E2.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSerum E2 suppression
    Study

    n = 36

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1, 3, or 5 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Cetrorelix acetate administration led to a rapid, marked, and reversible suppression of serum LH, E2, and to a lesser extent FSH concentrations.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy premenopausal women, cetrorelix suppressed FSH less markedly than LH and E2.

    In plain wordsIn healthy premenopausal women, cetrorelix suppressed FSH less markedly than LH and E2.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSerum FSH suppression
    Study

    n = 36

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1, 3, or 5 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Cetrorelix acetate administration led to a rapid, marked, and reversible suppression of serum LH, E2, and to a lesser extent FSH concentrations.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy women, cetrorelix shifted the serum LH maximum by a median 4.0 days versus the control cycle.

    In plain wordsIn healthy women, cetrorelix shifted the serum LH maximum by a median 4.0 days versus the control cycle.

    Peptide
    Cetrorelix
    Outcome
    IncreaseLH maximum timing
    Study

    n = 12

    Comparator
    Control cycle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Measurements

    LH maximum shift
    4 days
    1 mg

    Source sentences

    Summary
    The median intra-individual shifts between treatment and control cycle were -1.0, 4.0, 8.0, and 9.5 days for serum LH maximum and -1.0, 4.5, 7.0, and 10.0 days for ovulation following placebo or 1, 3, and 5 mg cetrorelix acetate, peptide base, respectively.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy women, cetrorelix shifted the serum LH maximum by a median 8.0 days versus the control cycle.

    In plain wordsIn healthy women, cetrorelix shifted the serum LH maximum by a median 8.0 days versus the control cycle.

    Peptide
    Cetrorelix
    Outcome
    IncreaseLH maximum timing
    Study

    n = 12

    Comparator
    Control cycle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Measurements

    LH maximum shift
    8 days
    3 mg

    Source sentences

    Summary
    The median intra-individual shifts between treatment and control cycle were -1.0, 4.0, 8.0, and 9.5 days for serum LH maximum and -1.0, 4.5, 7.0, and 10.0 days for ovulation following placebo or 1, 3, and 5 mg cetrorelix acetate, peptide base, respectively.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  8. 08HumanNon-randomized trialEfficacy outcome

    In healthy women, cetrorelix shifted the serum LH maximum by a median 9.5 days versus the control cycle.

    In plain wordsIn healthy women, cetrorelix shifted the serum LH maximum by a median 9.5 days versus the control cycle.

    Peptide
    Cetrorelix
    Outcome
    IncreaseLH maximum timing
    Study

    n = 12

    Comparator
    Control cycle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    5 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Measurements

    LH maximum shift
    9.5 days
    5 mg

    Source sentences

    Summary
    The median intra-individual shifts between treatment and control cycle were -1.0, 4.0, 8.0, and 9.5 days for serum LH maximum and -1.0, 4.5, 7.0, and 10.0 days for ovulation following placebo or 1, 3, and 5 mg cetrorelix acetate, peptide base, respectively.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  9. 09HumanNon-randomized trialEfficacy outcome

    In healthy women, cetrorelix shifted ovulation by a median 4.5 days versus the control cycle.

    In plain wordsIn healthy women, cetrorelix shifted ovulation by a median 4.5 days versus the control cycle.

    Peptide
    Cetrorelix
    Outcome
    IncreaseOvulation timing
    Study

    n = 12

    Comparator
    Control cycle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Measurements

    Ovulation shift
    4.5 days
    1 mg

    Source sentences

    Summary
    The median intra-individual shifts between treatment and control cycle were -1.0, 4.0, 8.0, and 9.5 days for serum LH maximum and -1.0, 4.5, 7.0, and 10.0 days for ovulation following placebo or 1, 3, and 5 mg cetrorelix acetate, peptide base, respectively.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  10. 10HumanNon-randomized trialEfficacy outcome

    In healthy women, cetrorelix shifted ovulation by a median 7.0 days versus the control cycle.

    In plain wordsIn healthy women, cetrorelix shifted ovulation by a median 7.0 days versus the control cycle.

    Peptide
    Cetrorelix
    Outcome
    IncreaseOvulation timing
    Study

    n = 12

    Comparator
    Control cycle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Measurements

    Ovulation shift
    7 days
    3 mg

    Source sentences

    Summary
    The median intra-individual shifts between treatment and control cycle were -1.0, 4.0, 8.0, and 9.5 days for serum LH maximum and -1.0, 4.5, 7.0, and 10.0 days for ovulation following placebo or 1, 3, and 5 mg cetrorelix acetate, peptide base, respectively.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.
  11. 11HumanNon-randomized trialEfficacy outcome

    In healthy women, cetrorelix shifted ovulation by a median 10.0 days versus the control cycle.

    In plain wordsIn healthy women, cetrorelix shifted ovulation by a median 10.0 days versus the control cycle.

    Peptide
    Cetrorelix
    Outcome
    IncreaseOvulation timing
    Study

    n = 12

    Comparator
    Control cycle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    5 mg peptide base · subcutaneous · single doseAs given in this study (human).

    Measurements

    Ovulation shift
    10 days
    5 mg

    Source sentences

    Summary
    The median intra-individual shifts between treatment and control cycle were -1.0, 4.0, 8.0, and 9.5 days for serum LH maximum and -1.0, 4.5, 7.0, and 10.0 days for ovulation following placebo or 1, 3, and 5 mg cetrorelix acetate, peptide base, respectively.
    3 context sentences
    Summary · context
    Healthy, premenopausal women aged 19 to 35 years.
    Summary · context
    Single subcutaneous morning doses of cetrorelix acetate (1, 3, or 5 mg peptide base) were investigated in a randomized, single-blind, placebo-controlled, parallel-group design.
    Summary · context
    After a control cycle, 36 women received cetrorelix acetate (12 per dose) and 12 received placebo on the eighth individual cycle day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.